Floatz logo

Opc-34712

Nervous System Diseases

Otsuka Pharmaceutical Development & Commercialization, Inc.Phase 3Dormant
BB
66/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
54/ 100
Competitive Position
89/ 100

Competitive context

35 Active assets in the Nervous System Diseases cohort.

Asset / SponsorPhaseRating
Ginkgolide
Second Affiliated Hospital, School of Medicine, Zhejiang University
Phase 4BB
Guanfacine
Maimonides Medical Center
Phase 4BB
Guanfacine
Maimonides Medical Center
Phase 4BB
Live Combined Bifidobacterium
Beijing Friendship Hospital
Phase 4BB
Live Combined Bifidobacterium,Lactobacillus And Enterococcus Capsules
Beijing Friendship Hospital
Phase 4BB

View all 50 →

Same molecule, other indications

Opc-34712 is also rated in:

depressive disorderDormant
A
Indicative ·
82 / 100
View asset →
major depressive disorderDormant
BBB
Indicative ·
75 / 100
View asset →
schizophreniaDormant
BBB
Indicative ·
75 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →